AZD7442
Sign in to saveAlso known as tixagevimab/cilgavimab, AZD8895/AZD1061, Evusheld, COV2-2130/COV2-2196
Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections (one injection per monoclonal antibody, given in immediate succession).
Key facts
- Drug.MedlinePlus
- a621058
- Drug.DailyMedID
- Tixagevimab
- Drug.pregnancy_AU
- B2
- Drug.tradename
- Evusheld
- Drug.type
- mab
- Drug.image
- Tixagevimab-cilgavimab binding SARS-CoV-2 spike protein 7L7E.png
- Drug.caption
- Tixagevimab (teal, right) and cilgavimab (purple, left) binding the spike protein . From .
- Drug.component1
- Tixagevimab
- Drug.class1
- Monoclonal antibody
- Drug.component2
- Cilgavimab
- Drug.class2
- Monoclonal antibody
- Drug.routes_of_administration
- Intramuscular
- Drug.ATC_prefix
- None
- Drug.ATC_suffix
- D03
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_UK
- POM
via Wikipedia infobox
Clinical Trials
16 registered- PHASE1COMPLETEDAZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in PediatricsAstraZeneca · NCT05281601
- PHASE1COMPLETEDStudy to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy ParticipantsAstraZeneca · NCT05166421
- PHASE3COMPLETEDAZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)National Institute of Allergy and Infectious Diseases (NIAID) · NCT05780437
- COMPLETEDPREP (Pre-Exposure Prophylaxis) of COVID-19Ghady Haidar · NCT05461378
- PHASE1COMPLETEDPhase I Double-blind, Placebo-controlled Study of AZD7442AstraZeneca · NCT04896541
- PHASE3COMPLETEDPhase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in AdultsAstraZeneca · NCT04625972
Wikidata facts
Show 2 more facts
- Commons category
- AZD7442
- name
- Evusheld
via Wikidata · CC0
~4 min read
Article
5 sectionsContents
- Development
- Society and culture
- Legal status
- References
- External links
Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2 used to prevent COVID-19. It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca. It is co-packaged and given as two separate consecutive intramuscular injections (one injection per monoclonal antibody, given in immediate succession).
== Development ==